These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 12806956)

  • 21. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis.
    Smith TJ; Hillner BE; Desch CE
    J Natl Cancer Inst; 1993 Sep; 85(18):1460-74. PubMed ID: 8360929
    [No Abstract]   [Full Text] [Related]  

  • 22. High cost of cancer treatment doesn't reflect benefits, say specialists.
    Hawkes N
    BMJ; 2011 Sep; 343():d6220. PubMed ID: 21952509
    [No Abstract]   [Full Text] [Related]  

  • 23. Economic sustainability of immune-checkpoint inhibitors: the looming threat.
    Verma V
    Nat Rev Clin Oncol; 2018 Dec; 15(12):721-722. PubMed ID: 30127492
    [No Abstract]   [Full Text] [Related]  

  • 24. Improving transparency of methods and results in cost-effectiveness analyses for cancer prevention, treatment and control.
    Catalá-López F; Ridao M
    Med Clin (Barc); 2017 Jan; 148(1):43-45. PubMed ID: 27567331
    [No Abstract]   [Full Text] [Related]  

  • 25. 'Value for money' requirement in treatment choices.
    Zielinski C
    Eur J Cancer; 2002 Jul; 38(10):1291. PubMed ID: 12168603
    [No Abstract]   [Full Text] [Related]  

  • 26. Childhood cancer: cure at what cost?
    Morris-Jones PH; Craft AW
    Arch Dis Child; 1990 Jun; 65(6):638-40. PubMed ID: 2116116
    [No Abstract]   [Full Text] [Related]  

  • 27. Gain, but what, how much and at what cost?
    Schrijvers D
    Ann Oncol; 2010 Jul; 21(7):1562-1563. PubMed ID: 20573850
    [No Abstract]   [Full Text] [Related]  

  • 28. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence-based medicine: can it be applied to stimulation of erythropoiesis for patients with malignancy?
    Rizzo JD
    Best Pract Res Clin Haematol; 2005; 18(3):439-48. PubMed ID: 15792918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Economic analysis of adverse events in cancer treatment].
    Koinuma N; Takeyoshi H
    Nihon Rinsho; 2003 Jun; 61(6):1030-8. PubMed ID: 12806956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care.
    Uyl-de Groot CA
    Eur J Cancer; 2006 Nov; 42(17):2862-6. PubMed ID: 17008095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methodological issues in the economic analysis of cancer treatments.
    Tappenden P; Chilcott J; Ward S; Eggington S; Hind D; Hummel S
    Eur J Cancer; 2006 Nov; 42(17):2867-75. PubMed ID: 17023160
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.